Mirae Asset Global Investments Co., Ltd. Biotechnology

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
NVO Novo Nordisk A S	$201B	$62.8 Million 0.26% of portfolio	729,965	Q4 2024 Added 53.52%
VRTX Vertex Pharmaceuticals Inc	$122B	$48.1 Million 0.2% of portfolio	119,549	Q4 2024 Added 16.88%
REGN Regeneron Pharmaceuticals, Inc.	$75.3B	$39.5 Million 0.16% of portfolio	55,426	Q4 2024 Added 21.6%
MDGL Madrigal Pharmaceuticals, Inc.	$6.09B	$21.7 Million 0.09% of portfolio	70,179	Q4 2024 Reduced 8.65%
ALNY Alnylam Pharmaceuticals, Inc.	$29.2B	$2.15 Million 0.01% of portfolio	9,130	Q4 2024 Reduced 12.45%
ARGX Argenx Se	$34.6B	$2.02 Million 0.01% of portfolio	3,285	Q4 2024 Reduced 3.72%
RPRX Royalty Pharma PLC	$14.6B	$1.91 Million 0.01% of portfolio	75,068	Q4 2024 Reduced 1.27%
MRNA Moderna, Inc.	$12.2B	$1.91 Million 0.01% of portfolio	45,821	Q4 2024 Reduced 54.74%
INCY Incyte Corp	$16.3B	$1.62 Million 0.01% of portfolio	23,467	Q4 2024 Added 12.09%
TECH Bio Techne Corp	$2.4B	$1.2 Million 0.0% of portfolio	16,650	Q4 2024 Added 46.63%
UTHR United Therapeutics Corp	$14.7B	$1.17 Million 0.0% of portfolio	3,302	Q4 2024 Reduced 9.46%
PCVX Vaxcyte, Inc.	$4.4B	$1.09 Million 0.0% of portfolio	13,264	Q4 2024 Reduced 11.64%
GMAB Genmab A/S	$15B	$1.04 Million 0.0% of portfolio	49,727	Q4 2024 Added 229.86%
ASND Ascendis Pharma A/S	$8.55B	$973,000 0.0% of portfolio	7,074	Q4 2024 Reduced 0.94%
SRPT Sarepta Therapeutics, Inc.	$9.02B	$798,000 0.0% of portfolio	6,570	Q4 2024 Added 9.46%
BGNE Bei Gene, Ltd.	$23.5B	$625,000 0.0% of portfolio	3,388	Q4 2024 Reduced 9.53%
VKTX Viking Therapeutics, Inc.	$2.13B	$534,000 0.0% of portfolio	13,284	Q4 2024 New
BMRN Biomarin Pharmaceutical Inc	$12.8B	$498,000 0.0% of portfolio	7,590	Q4 2024 Reduced 9.69%
LEGN Legend Biotech Corp	$6.15B	$478,000 0.0% of portfolio	14,699	Q4 2024 Reduced 48.51%
SMMT Summit Therapeutics Inc.	$3.66B	$470,000 0.0% of portfolio	26,383	Q4 2024 Added 0.68%
INSM Insmed Inc	$10.6B	$441,000 0.0% of portfolio	6,401	Q4 2024 Added 2.99%
BNTX Bio N Tech Se	$26.4B	$400,000 0.0% of portfolio	3,513	Q4 2024 Reduced 10.63%
EXEL Exelixis, Inc.	$12.1B	$316,000 0.0% of portfolio	9,516	Q4 2024 Reduced 7.76%
ROIV Roivant Sciences Ltd.	$7.47B	$286,000 0.0% of portfolio	24,258	Q4 2024 Reduced 9.31%
JAZZ Jazz Pharmaceuticals PLC	$8.98B	$248,000 0.0% of portfolio	2,015	Q4 2024 Reduced 18.62%
RVMD Revolution Medicines, Inc.	$3.55B	$245,000 0.0% of portfolio	5,606	Q4 2024 Reduced 7.2%
HALO Halozyme Therapeutics, Inc.	$8.04B	$202,000 0.0% of portfolio	4,240	Q4 2024 Reduced 7.46%
CYTK Cytokinetics Inc	$4.41B	$185,000 0.0% of portfolio	3,933	Q4 2024 Reduced 7.59%
BPMC Blueprint Medicines Corp	$5.46B	$184,000 0.0% of portfolio	2,117	Q4 2024 Reduced 7.59%
IONS Ionis Pharmaceuticals Inc	$4.45B	$183,000 0.0% of portfolio	5,262	Q4 2024 Reduced 0.49%
BBIO Bridge Bio Pharma, Inc.	$4.96B	$172,000 0.0% of portfolio	6,298	Q4 2024 Reduced 7.4%
NUVL Nuvalent, Inc.	$3.31B	$171,000 0.0% of portfolio	2,187	Q4 2024 Added 1.86%
CRNX Crinetics Pharmaceuticals, Inc.	$1.79B	$157,000 0.0% of portfolio	3,090	Q4 2024 Added 6.74%
KRYS Krystal Biotech, Inc.	$4.53B	$150,000 0.0% of portfolio	958	Q4 2024 Reduced 7.8%
ACLX Arcellx, Inc.	$2.67B	$137,000 0.0% of portfolio	1,802	Q4 2024 Reduced 7.3%
AXSM Axsome Therapeutics, Inc.	$5.5B	$136,000 0.0% of portfolio	1,615	Q4 2024 Reduced 6.97%
ADMA Adma Biologics, Inc.	$3.1B	$135,000 0.0% of portfolio	7,877	Q4 2024 Reduced 6.56%
IMVT Immunovant, Inc.	$3.55B	$134,000 0.0% of portfolio	4,891	Q4 2024 Reduced 7.61%
SRRK Scholar Rock Holding Corp	$1.91B	$134,000 0.0% of portfolio	3,120	Q4 2024 Added 7.77%
APLS Apellis Pharmaceuticals, Inc.	$2.89B	$132,000 0.0% of portfolio	4,145	Q4 2024 Reduced 5.88%
RARE Ultragenyx Pharmaceutical Inc.	$2.91B	$129,000 0.0% of portfolio	3,077	Q4 2024 Reduced 7.68%
ZLAB Zai Lab LTD	$3.43B	$120,000 0.0% of portfolio	4,603	Q4 2024 Added 1.9%
PTCT Ptc Therapeutics, Inc.	$3.65B	$116,000 0.0% of portfolio	2,570	Q4 2024 Reduced 7.62%
RNA Avidity Biosciences, Inc.	$1.55B	$115,000 0.0% of portfolio	3,976	Q4 2024 Reduced 6.14%
RYTM Rhythm Pharmaceuticals, Inc.	$2.95B	$114,000 0.0% of portfolio	2,048	Q4 2024 Reduced 7.37%
VRNA Verona Pharma PLC	$3.87B	$114,000 0.0% of portfolio	2,465	Q4 2024 Reduced 5.56%
CRSP Crispr Therapeutics Ag	$3.4B	$111,000 0.0% of portfolio	2,844	Q4 2024 Reduced 7.66%
VCYT Veracyte, Inc.	$2.54B	$102,000 0.0% of portfolio	2,583	Q4 2024 Reduced 7.02%
ACAD Acadia Pharmaceuticals Inc	$3.08B	$101,000 0.0% of portfolio	5,545	Q4 2024 Reduced 7.57%
XENE Xenon Pharmaceuticals Inc.	$2.43B	$99,000 0.0% of portfolio	2,541	Q4 2024 Reduced 7.26%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.